Data from a phase 2 trial of Roche's oral BTK inhibitor fenebrutinib have shown "near-complete suppression" of disease activity and disability progression in relapsing multiple sclerosis (MS). The ...
Since the launch of the Crossword in 1942, The Times has captivated solvers by providing engaging word and logic games. In 2014, we introduced the Mini Crossword — followed by Spelling Bee, Letter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback